BIOLASE (NASDAQ:BIOL) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL) in a report issued on Saturday. The brokerage issued a sell rating on the medical technology company’s stock.

Several other equities analysts also recently weighed in on the company. Benchmark restated a “speculative buy” rating and issued a $0.40 target price on shares of BIOLASE in a research report on Wednesday, October 2nd. Ascendiant Capital Markets decreased their price objective on BIOLASE from $3.50 to $2.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd.

BIOLASE Price Performance

Shares of BIOL stock opened at $0.01 on Friday. The company has a market cap of $267,256.00, a price-to-earnings ratio of 0.00 and a beta of 0.67. BIOLASE has a 1-year low of $0.02 and a 1-year high of $1.94. The stock has a 50 day simple moving average of $0.01 and a 200-day simple moving average of $0.05.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.